We announced today that our Phase 3 trial of mRNA-1083, an investigational combination #vaccine against #influenza and #COVID19, has met its primary endpoints.
mRNA-1083 comprises components of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283,…
pic.twitter.com/BRuYBsBVag